Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban for Early Neurological Deterioration in Acute Ischemic Stroke
NCT06587347Phase 3Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirofiban in ischemic stroke (2 arms), sponsored by Capital Medical University. Primary endpoint: Proportion of patients experiencing neurological deterioration within 24 hours after intravenous thrombolysis. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06587347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06587347.